Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-28T12:53:18.618Z Has data issue: false hasContentIssue false
  • English
  • Français

Targeting the molecular basis for tumour hypoxia

Published online by Cambridge University Press:  15 April 2005

Veronica A. Carroll  and
Margaret Ashcroft
Veronica A. Carroll
Affiliation:
Cell Growth Regulation and Angiogenesis Laboratory, Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK.
Margaret Ashcroft
Affiliation:
Cell Growth Regulation and Angiogenesis Laboratory, Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK.
Get access Rights & Permissions [Opens in a new window]

Abstract

Tumour hypoxia stems from impaired oxygen delivery as a result of a disorganised tumour vasculature and inadequate blood supply. Hypoxic tumours are highly resistant to chemotherapy and radiation therapy and correlate with a poor patient prognosis. Hypoxia is a powerful stimulus for the expression of genes involved in cell survival and angiogenesis. A key factor in this process is hypoxia-inducible factor (HIF), which regulates transcription of hypoxia-activated genes. Efforts are currently under way to develop targeted cancer therapeutics to hypoxia-activated pathways, and in particular to the transcription factor HIF.

Keywords

Tumour hypoxiaHIFtargeted cancer therapeuticsangiogenesis
Type
Review Article
Information
Expert Reviews in Molecular Medicine , Volume 7 , Issue 6 , 15 April 2005 , pp. 1 - 16
Copyright
© Cambridge University Press 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)